Drugs / BNC105P
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03454165 | Mar 2018 → Jan 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01624493 | Oct 2012 → Jul 2014 | ovarian cancer | Hoosier Cancer Research Network | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01034631 Comparator | Jan 2010 → Dec 2016 | renal cell carcinoma | Hoosier Cancer Research Network | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNC105P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01624493 ↗ |
| Known as | BNC105 | “BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.” NCT03454165 ↗ |
| Action | Inhibit | “BNC105P inhibits tubulin polymerization” PMID 25788492 ↗ Mar 2015 |
| Modality | Other / unclassified | “BNC105P, a vascular disrupting agent” PMID 34108261 ↗ Jun 2021 |